Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II. Primary objective is to evaluate safety and tolerability of KESONOTIDE™ as a monotherapy in participants with advanced/metastatic solid cancers. Secondary objective is to characterise the pharmacokinetics of KESONOTIDE™. Phase I study will enrol 20-32 participants and Phase II approximately 80 participants.

Trial Details

NCT ID
NCT06926075
Phase
PHASE1 / PHASE2
Sponsor
Filamon LTD
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • A novel hGIIA-Vimentin Inhibitor
  • Dose expansion
Locations (sample)
  • Kogarah, New South Wales, Australia|-33.9681,151.13564
  • Liverpool, New South Wales, Australia|-33.91938,150.92588
  • Miranda, New South Wales, Australia|-34.03857,151.10005

Key Eligibility Criteria

  • Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed…
  • Has an ECOG performance status score of 0 or 1.
  • Has a life expectancy of \> 12 weeks in the opinion of the investigator.
  • Measurable or evaluable disease by CT/MRI according to RECIST v1.1, except for prostate and breast cancer (bone only metastases are acceptable) and…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →